Cargando…
The Alzheimer’s disease drug development landscape
BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallmarks of t...
Autores principales: | van Bokhoven, Pieter, de Wilde, Arno, Vermunt, Lisa, Leferink, Prisca S., Heetveld, Sasja, Cummings, Jeffrey, Scheltens, Philip, Vijverberg, Everard G. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582156/ https://www.ncbi.nlm.nih.gov/pubmed/34763720 http://dx.doi.org/10.1186/s13195-021-00927-z |
Ejemplares similares
-
The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019) -
Clinical Features of Patients with Alzheimer's Disease and a History of Traumatic Brain Injury
por: van Amerongen, Suzan, et al.
Publicado: (2022) -
Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016) -
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017) -
Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)